Bioperfectus SARS-CoV-2 Antigen Self-Test Approved by BASG

Company news


 Today, we are honored to inform you that#BioperfectusNovel Corona Virus (SARS-CoV-2) AgRapid Test Kit has beenapproved for Self-Test Use by Austrian Federal Office for Safety in Health Care.


We would like to thank you our Austria exclusive distributor HVD Life Science Vertriebs GmbH, Vienna Austria and special thanks to Werner Buergler and his team for all promising partnership in Austria.


We will continue to scale up our innovation to deliver high-quality and highly-accurate rapid test to speed up the end of#sarscov2.


Click here to take a glimpse of our rapid antigen test leaflet.


Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.


Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.


Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).